ADAP Bullish Divergence, Low Risk PlayBullish divergence on the MACD and ADX.
Price near last low.
Low risk play with high potential in the short term.
−0.5229USD
−114.31 MUSD
60.51 MUSD
200.12 M
About Adaptimmune Therapeutics plc
Sector
Industry
CEO
Adrian Rawcliffe
Website
Headquarters
Abingdon
Employees (FY)
449
Founded
2008
ISIN
US00653A1079
FIGI
BBG008G65WC2
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
$ADAP is gonna fall todayPupm&Dump trading strategy idea.
$ADAP is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $6,29;
stop-loss — $6,52;
take-profit — $5,82/MOC
Do not view
$ADAPDragon pattern.
Weekly classic bullish divergence on the MACD.
Stop = Close below resistance
1st Target = Resistance/0.236 fib extension
2nd Target = Resistance/0.5 fib extension
BUY ADAP - ADAPTIMMUNE THERAPEUTICS - STRONG BUY ON WEEKLY CHARTBUY ADAP - ADAPTIMMUNE THERAPEUTICS - STRONG BUY ON WEEKLY CHART
A Fantastic Bullish Setup on ADAPThis stock has shown breakout earlier creating wave 1
then it created its wave 3 when it had its stronger breakout
now its doing a flat sideways tight range wave 4
The NEXT breakout will be a wave 5 up
SPEAR T-cell Platform Delivers Initial Responses in Four Solid TAdaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
--------------------------------------------------------------
Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers.
-------------------------------
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in EGJIn the Surpass trial, three of the first four patients treated with ADP-A2M4CD8 had smaller tumors at the last checkup than they did at the outset.
----------------------------------------------------------
Eight out of 16 patients with synovial sarcoma have shown partial responses to treatment wit
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
